Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) ("Nyxoah" or the "Company"), a medical technology company focused on developing innovative solutions for Obstructive Sleep Apnea (OSA), today announced that it has received $15 million (€13.8 million) in proceeds from the second tranche of its loan facility with the European Investment Bank (EIB). The drawdown follows the recent confirmation that the Company had satisfied the predefined criteria required to access this tranche.

With this drawdown, Nyxoah has raised approximately $110 million in total new capital in June 2026, combining the proceeds of its underwritten public offering with this non-dilutive EIB financing.